Biochemical Genetics

, Volume 51, Issue 7–8, pp 564–574 | Cite as

Association of TIMP-1 and TIMP-2 Gene Polymorphisms with Progression of Liver Fibrosis in Patients with Type C Chronic Liver Disease

  • Yuichiro Ikebuchi
  • Chihiro Ishida
  • Kinya Okamoto
  • Yoshikazu Murawaki
Article

Abstract

We examined the association of TIMP-1 and TIMP-2 gene polymorphisms with the progression of chronic liver disease related to the hepatitis C virus (HCV). We used PCR to analyze 188 patients with HCV-related liver disease (95 with chronic hepatitis and 93 with cirrhosis) for TIMP-1 372 T/C and TIMP-2 –418 G/C polymorphisms. Comparing chronic hepatitis and cirrhosis, there were no significant differences in TIMP-1 and TIMP-2 gene polymorphisms. Among chronic hepatitis patients, TIMP-2 –418 G homozygotes showed significantly faster fibrosis progression than C carriers. Among cirrhotic patients, males with the TIMP-1 372 T allele developed cirrhosis at a younger age, and patients who were homozygous for the higher-transcription TIMP-2 –418 G allele had significantly lower serum albumin concentrations. These results suggest that faster progression of liver fibrosis could be associated with TIMP-2 –418 G homozygotes.

Keywords

TIMP-1 TIMP-2 Liver fibrosis Genotype 

References

  1. Arthur MJP (2000) Fibrogenesis II: metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279:G245–G249PubMedGoogle Scholar
  2. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727PubMedCrossRefGoogle Scholar
  3. Bekkaoui F, Poisson I, Crosby W, Cloney L, Duck P (1996) Cycling probe technology with RNase H attached to an oligonucleotide. Biotechniques 20:240–248PubMedGoogle Scholar
  4. Bernardo MM, Fridman R (2003) TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 374:739–745PubMedCrossRefGoogle Scholar
  5. De Clerck YA, Darville MI, Eeckhout Y, Rousseau GG (1994) Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinase-2 (TIMP-2). Gene 139:185–191PubMedCrossRefGoogle Scholar
  6. Duck P, Alvarado-Urbina G, Burdick B, Collier B (1990) Probe amplifier system based on chimeric cycling oligonucleotides. Biotechniques 9:142–148PubMedGoogle Scholar
  7. Faisst S, Meyer S (1992) Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res 20:3–26PubMedCrossRefGoogle Scholar
  8. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36:986–992PubMedGoogle Scholar
  9. Friedman SL (2003) Liver fibrosis: from bench to bedside. J Hepatol 38:S38–S53PubMedCrossRefGoogle Scholar
  10. Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, Mochizuki M, Kimura T, Saitoh W, Iizuka T, Kiwamoto T, Sekizawa K (2005) Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms. Respirology 10:27–30PubMedCrossRefGoogle Scholar
  11. Hemmann S, Graf J, Roderfeld M, Roeb E (2007) Expression of MMPs and TIMPs in liver fibrosis: a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46:955–975PubMedCrossRefGoogle Scholar
  12. Hinterseher I, Krex D, Kuhlisch E, Schmidt KG, Pilarsky C, Schneiders W, Pilarsky C, Schneiders W, Saeger HD, Bergert H (2007) Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. World J Surg 31:2248–2254PubMedCrossRefGoogle Scholar
  13. Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, Nomura A, Ohtsuka M, Sekizawa K (2001) Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 18:748–752PubMedCrossRefGoogle Scholar
  14. Indelicato M, Chiarenza V, Libra M, Malaponte G, Bevelacqua V, Marchini M, McCubrey JA, Stivala F, Scorza R, Mazzarino MC (2006) Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. J Clin Lab Anal 20:173–176PubMedCrossRefGoogle Scholar
  15. Kang S, Zhao X, Xing H, Wang N, Zhou R, Chen S, Li W, Zhao J, Duan Y, Sun D, Li Y (2008) Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis. Environ Mol Mutagen 49:226–231PubMedCrossRefGoogle Scholar
  16. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y (2007) FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 45:297–306PubMedCrossRefGoogle Scholar
  17. Krex D, Röhl H, König IR, Ziegler A, Schackert HK, Schackert G (2003) Tissue inhibitor of metalloproteinases-1, -2 and -3 polymorphisms in a white population with intracranial aneurysms. Stroke 34:2817–2821PubMedCrossRefGoogle Scholar
  18. Marcellin P (2009) Hepatitis B and hepatitis C in 2009. Liver Int 29:S1–S8CrossRefGoogle Scholar
  19. Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47–S56PubMedCrossRefGoogle Scholar
  20. Meijer MJW, Mieremet-Ooms MAC, van Hogezand RA, Lamers CBHW, Hommes DW, Verspaget HW (2007) Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 13:2960–2966PubMedGoogle Scholar
  21. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H (1997) Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 26:1213–1219PubMedCrossRefGoogle Scholar
  22. Murawaki Y, Ikuta Y, Kawasaki H (1999) Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 281:109–120PubMedCrossRefGoogle Scholar
  23. Nie Q-H, Zhu C-L, Zhang Y-F, Yang J, Zhang J-C, Gao R-T (2010) Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci 55:1286–1295PubMedCrossRefGoogle Scholar
  24. O-charoenrat P, Khantapura P (2006) The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42:257–267PubMedCrossRefGoogle Scholar
  25. Polette M, Birembaut P (1998) Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30:1195–1202PubMedCrossRefGoogle Scholar
  26. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C: the ObsVirC, MetaVir, CliniVir, and DosVirC groups. Lancet 349:825–832PubMedCrossRefGoogle Scholar
  27. Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ (2003) Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124:352–360PubMedCrossRefGoogle Scholar
  28. Wei JC, Lee HS, Chen WC, Shiu LJ, Yang SF, Wong RH (2009) Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis. Ann Rheum Dis 68:1781–1786PubMedCrossRefGoogle Scholar
  29. Wei S, Chen Y, Chung L, Nagase H, Brew K (2003) Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. J Biol Chem 278:9831–9834PubMedCrossRefGoogle Scholar
  30. Yi YC, Chen M-K, Chen L-Y, Ho ES-C, Ying T-H, Wang P-H, Yang SF (2009) Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer. Clin Chim Acta 409:127–131PubMedCrossRefGoogle Scholar
  31. Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25:399–404PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yuichiro Ikebuchi
    • 1
  • Chihiro Ishida
    • 1
  • Kinya Okamoto
    • 1
  • Yoshikazu Murawaki
    • 1
  1. 1.Division of Medicine and Clinical Science, Department of Multidisciplinary Internal MedicineTottori University School of MedicineYonagoJapan

Personalised recommendations